227.21
3.91%
8.41
Icon Plc stock is traded at $227.21, with a volume of 541.99K.
It is up +3.91% in the last 24 hours and down -22.55% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$218.80
Open:
$219.5
24h Volume:
541.99K
Relative Volume:
0.67
Market Cap:
$18.30B
Revenue:
$8.33B
Net Income/Loss:
$714.43M
P/E Ratio:
36.65
EPS:
6.2
Net Cash Flow:
$1.18B
1W Performance:
-2.17%
1M Performance:
-22.55%
6M Performance:
-26.43%
1Y Performance:
-11.91%
Icon Plc Stock (ICLR) Company Profile
Icon Plc Stock (ICLR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-15-23 | Initiated | Truist | Buy |
Sep-13-23 | Initiated | TD Cowen | Outperform |
Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
Sep-07-22 | Initiated | UBS | Buy |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
May-24-22 | Initiated | Guggenheim | Buy |
Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
Jul-14-21 | Initiated | Citigroup | Neutral |
Apr-13-21 | Resumed | BofA Securities | Neutral |
Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Mar-03-21 | Initiated | Barclays | Equal Weight |
Mar-01-21 | Upgrade | UBS | Neutral → Buy |
Feb-26-21 | Upgrade | Truist | Hold → Buy |
Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
Mar-02-20 | Initiated | Deutsche Bank | Hold |
Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Neutral |
Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Jul-26-19 | Upgrade | UBS | Sell → Neutral |
Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-09-18 | Initiated | UBS | Sell |
Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-15-18 | Reiterated | Mizuho | Neutral |
Jan-19-18 | Initiated | Evercore ISI | Outperform |
Oct-27-17 | Reiterated | Barclays | Equal Weight |
Sep-11-17 | Initiated | BofA/Merrill | Buy |
Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
Jul-27-17 | Reiterated | Mizuho | Neutral |
Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
Life Sciences BPO Market Set to Witness Significant Growth by 2024-2031:Catalent, Inc., Covance, Inc., Fareva, - EIN News
Icon (FRA:IJF) GF Value Rank : 10 (As of Nov. 04, 2024) - GuruFocus.com
ICON Plc stock touches 52-week low at $219.87 amid market shifts - Investing.com
Icon PLC (ICLR) Trading 3.72% Higher on Oct 2 - GuruFocus.com
ICON's $650 Million Power Play: Can This Bold Move Reverse a 21% Stock Plunge? - Yahoo Finance UK
Baird Downgrades ICON Public Limited (ICLR) - MSN
Icon plc Strengthens Investor Confidence with Secured Notes - TipRanks
Earnings call: ICON PLC faces headwinds, eyes strategic growth By Investing.com - Investing.com Australia
Earnings call: ICON PLC faces headwinds, eyes strategic growth - Investing.com India
Icon PLC (ICLR) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
Pharmaceutical Contract Sales Outsourcing (CSO) Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
Icon PLC (ICLR) Q3 2024 Earnings Call Highlights: Navigating Cha - GuruFocus.com
ICON Plc stock touches 52-week low at $227.56 amid market shifts - Investing.com Australia
U.S. Markets Finished Mixed Thursday As Tesla Led, Icon PLC Lagged - Barron's
ICON stock slips after guidance cut (ICLR:NASDAQ) - Seeking Alpha
Icon PLC Down Over 19%, on Pace for Largest Percent Decrease Since March 1999 — Data Talk - Morningstar
ICON Plc stock touches 52-week low at $227.56 amid market shifts By Investing.com - Investing.com South Africa
Baird downgrades ICON plc stock, slashes outlook on lower earnings and revenue guidance - Investing.com
S&P 500 Futures Up in Premarket Trading; Icon PLC, Darling Ingredients Lag - Barron's
ICON revenue slumps 1.2% to USD 2,030M in Q3 2024 - Medical Buyer
Icon PLC: Q3 Earnings Snapshot - Houston Chronicle
Icon PLC (ICLR) Lags Q3 Earnings and Revenue Estimates - Yahoo Finance
ICON Reports Third Quarter 2024 Results - sharewise
ICON Reports Mixed Q3 Results, Secures Key Partnership - TipRanks
Icon PLC: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
ICON plc shares tumble as Q3 results miss estimates, guidance cut - Investing.com Australia
ICON plc shares tumble as Q3 results miss estimates, guidance cut By Investing.com - Investing.com South Africa
Imaging CRO Market Is Booming Worldwide 2025-2030 | WORLDCARE - openPR
Icon PLC (ICLR) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Randomization and Trial Supply Management Market 2024-2031- Calyx, Almac, ICON plc, Trialogics, IBM, Medpace CRO, Endpoi – IndiaPolitics.com - IndiaPolitics.com
Redburn Atlantic Initiates Coverage of ICON Public Limited (ICLR) with Neutral Recommendation - Nasdaq
ICON plc stock faces Neutral rating as analyst flags downside risk to growth projections - Investing.com Australia
Biomarker Research Services Market Synopsis: Trends, Industry Insights, and Growth Forecast 2024-2031 |BioIVT, - EIN News
Onco-hematology Molecular Testing Market Size to Reach USD 1.5 billion by 2031 with a 12.5% CAGR, Boosted by Next-Generation Blood Cancer Diagnostics| Exclusive Report by Transparency Market Research, Inc. - GlobeNewswire Inc.
ICON plc's SWOT analysis: biotech recovery boosts stock amid industry shifts - Investing.com India
ICON plc Schedules Third Quarter 2024 Earnings Conference Call - sharewise
ICON plc Announces Q3 2024 Earnings Call - TipRanks
The collapse of ISG is the biggest in the sector since Carillion in 2018 - Company Rescue
Here's Why ICON (NASDAQ:ICLR) Has Caught The Eye Of Investors - Simply Wall St
Balfour Beatty moves to support subcontractors to alleviate ISG falloutreport - Proactive Investors UK
Icon Energy Corp. announces the delivery of M/V Bravo and the signing of a term loan facility for up to $91.5 million - Dry Bulk
Insignia Financial Becomes Major TABCORP Stakeholder - TipRanks
Icon PLC (ICLR) Trading Down 3.25% on Sep 25 - GuruFocus.com
Developer behind £12m tech hub meant to 'level up' region has gone bust - South Wales Argus
Imperial Brands Advances Share Buyback Plan - TipRanks
ISG collapse highlights how infrastructure funds 'learnt lessons from Carillion' - Proactive Investors USA
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):